GlassScriptPhysician profile
Joel Christopher Cobb
NPI 1124132485
$2,014.61
in general payments reported to CMS, 2019-2025
28 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $147 · 2021: $47.99 · 2022: $243 · 2023: $543 · 2024: $407 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $340.72 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $297.96 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $185.29 | 2019-2024 | |
| Abbvie INC. | $170.10 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $140.44 | 2022-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $113.97 | 2023-2024 | Spravato |
| Glaxosmithkline, LLC. | $85.94 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.91 | 2023-2025 | Xifaxan, Trulance |
| Genentech USA, INC. | $81.66 | 2020 | |
| Paratek Pharmaceuticals, INC. | $54.67 | 2022-2023 | Nuzyra |
| Novo Nordisk INC | $45.92 | 2022-2025 | Wegovy, Saxenda |
| Astellas Pharma US INC | $41.41 | 2019 | |
| Exact Sciences Corporation | $38.21 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $35.87 | 2024-2025 | Watchman Access System |
| Takeda Pharmaceuticals U.S.A., INC. | $33.25 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.04 | 2019-2022 | |
| Dexcom, INC. | $30.98 | 2022-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $29.92 | 2019-2020 | |
| Shire North American Group INC | $26.33 | 2019 | |
| Lundbeck LLC | $25.10 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $24.56 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.73 | 2019-2020 | |
| Amgen INC. | $14.82 | 2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.58 | 2019 | |
| Sanofi Pasteur INC. | $13.15 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.97 | 2020 | |
| Ironshore Pharmaceuticals INC. | $11.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.67 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.